Rhonda Farnum sold $36k of TBPH
SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc.. 4,000 shares at an average of $9.00, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +15RoleOfficer
- +6Trade size$36k at market
- 0Share of holdings soldSold 1.2% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026766, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | SOpen-market sale Ordinary Shares | -4,000 | $9.00 | $36k | 322,743 | Nov 13, 2024 |
Related signals
Other insiders at Theravance Biopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $227k 13,314 shares | -6% | |
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $264k 24,000 shares | -7% | |
| 1Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $36k 4,000 shares | -1% | |
| 1Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $36k 4,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.